Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy
Vanessa L Hull1,2,3, Yan Wang1,2, Jennifer McDonough4
1Department of Neurology, UC Davis School of Medicine, Sacramento, California, USA.
Annals of Clinical and Translational Neurology
|January 28, 2024
Summary
Canavan disease, a leukodystrophy, involves elevated brain N-acetyl-l-aspartate (NAA). Targeting astroglial NaDC3 transporters reversed NAA buildup and improved motor function in model mice, suggesting a therapeutic approach.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Canavan disease is a genetic leukodystrophy resulting from ASPA gene mutations.
- This leads to reduced aspartoacylase activity, causing elevated brain N-acetyl-l-aspartate (NAA) and myelin vacuolation.
- Astroglia, a type of glial cell, express the NaDC3 transporter (encoded by SLC13A3) responsible for NAA transport.
Purpose of the Study:
- To investigate the role of astroglial NaDC3 in Canavan disease pathogenesis.
- To evaluate the therapeutic potential of targeting NaDC3 in a mouse model of Canavan disease.
Main Methods:
- Utilized a mouse model of Canavan disease with aspartoacylase deficiency.
- Genetically deleted the Slc13a3 gene specifically in astrocytes of these model mice.
- Assessed brain NAA levels and motor function in the modified mice.
Main Results:
- Conditional deletion of astroglial Slc13a3 reversed the elevated brain NAA concentrations characteristic of Canavan disease.
- Mice with reduced astroglial NaDC3 expression showed significant improvements in motor function.
- These findings implicate astroglial NaDC3 in the accumulation of NAA in the Canavan disease brain.
Conclusions:
- Astroglial NaDC3 plays a significant role in elevating brain NAA levels in Canavan disease.
- Inhibiting astroglial NaDC3 transporter activity presents a promising therapeutic strategy for ameliorating human Canavan disease.
